Drug shortage: Rifampin Injection (RIFAMPIN)
FDA lists 4 presentations as Current. Availability: Unavailable (2), Limited Availability (1). Reason: Demand increase for the drug; Other. Companies: Mylan Institutional, a Viatris Company, Fresenius Kabi USA, LLC, Sanofi-Aventis U.S. LLC.
- Published by source
- 2021-02-17
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Mylan Institutional, a Viatris Company
- Products
- Rifampin Injection RIFAMPIN
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: Current — Unavailable
Remedy / actions:
- Estimated recovery: Q4 2026
- Check wholesalers for inventory
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2021-02-17
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #1025 | new | 2026-10-22 | b3d30c3f2ee1…5c0053 | 89adfe6edca1…65ff9e |
Chain head: #1076 8ad5adc30b9b…88ce20